

Association pathways in apoferritin-based nanovaccines: structural effects of pH-driven and direct assembly



FCFRP
FACULDADE DE CIÊNCIAS FARMACÉUTICAS
DE RIBEIRÃO PRETO - USP



DEMONARI, I.K¹; de ALMEIDA C. M. F.; PAIVA N. F.; VICENTINI F. T. M. C

¹School of Pharmaceuticals Science of Ribeirão Preto, University of São Paulo, Ribeirão Preto - Brazil.

Email: isabellakriunas@usp.br


INTRODUCTION

Apoferitin (ApFt) is a self-assembling globular protein widely investigated as a versatile biotechnological platform for immunotherapeutic delivery (1). This study evaluates the conformational and intermolecular effects arising from distinct assembly protocols for peptide (PPT) (2) and plasmid DNA (pDNA)-based nanovaccines (3).


The goal is to elucidate the structural dynamics of ApFt association with these biomolecules to optimize the development of protein-based nanocarriers.

METHODOLOGY


- 1st Association Pathways: pH- induced structural disassembly/reassembly



- 2nd Association Pathways: direct association



- Analysed by



RESULTS




Figure 1- ATR-FTIR spectra of apoferritin-based nanovaccines systems containing EGFRvIII peptide (left) and pDNA (right)

CONCLUSION

CD/FTIR show ApFt preserves its α -helical fold with ligand-specific surface rearrangements. The assembly route significantly influenced ApFt-PPT interactions, while ApFt-pDNA showed method-independent stability. These results underscore ApFt's structural robustness and adaptability, reinforcing its potential as a nanovaccine platform for rational formulation design.




Figure 2- Circular dichroism (CD) spectra of apoferritin-based nanovaccines systems (left) and the relative content (%) of secondary structure obtained from spectral deconvolution (right).

Financial support:



#2022/13379-7

#2025/26972-6

#403588/2021-9

#303534/2025-7

#408769/2024-6

#140091/2024-6

References:

- (1) CHAKRABORTI, S.; CHAKRABARTI, P. Advances in experimental medicine and biology, 2019:313-329.
- (2) de ALMEIDA, C. M. F., et al. European Journal of Pharmaceutics and Biopharmaceutics, 2025:114589.
- (3) PAIVA, N. F.; et al. Bionanoscience, 2025:1.